This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2002 Jul;87(7):3013-8.

doi: 10.1210/jcem.87.7.8665.

Somatostatin analogs in acromegaly

Pamela U Freda¹

Affiliations

PMID: 12107192
DOI: 10.1210/jcem.87.7.8665

Review

Somatostatin analogs in acromegaly

Pamela U Freda. J Clin Endocrinol Metab. 2002 Jul.

. 2002 Jul;87(7):3013-8.

doi: 10.1210/jcem.87.7.8665.

Author

Pamela U Freda¹

Affiliation

¹ Department of Medicine, Columbia University College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA.

PMID: 12107192
DOI: 10.1210/jcem.87.7.8665

No abstract available

PubMed Disclaimer

Similar articles

Distribution and functionality of the somatostatin receptor subtypes in acromegaly.
Saveanu A, Gunz G, Dufour H, Enjalbert A, Culler MD, Jaquet P. Saveanu A, et al. J Endocrinol Invest. 2003;26(8 Suppl):4-7. J Endocrinol Invest. 2003. PMID: 15233203 Review. No abstract available.
Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?
Chanson P. Chanson P. Eur J Endocrinol. 1997 Apr;136(4):359-61. doi: 10.1530/eje.0.1360359. Eur J Endocrinol. 1997. PMID: 9150692 No abstract available.
Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Protonotariou A, Lytras A. Tolis G, et al. Neuroendocrinology. 2006;83(3-4):249-57. doi: 10.1159/000095535. Epub 2006 Oct 13. Neuroendocrinology. 2006. PMID: 17047390 Review.
[Novel pharmacologic therapies in acromegaly].
Góth M, Hubina E, Kovács L, Szabolcs I. Góth M, et al. Orv Hetil. 2002 May 12;143(19 Suppl):1057-62. Orv Hetil. 2002. PMID: 12063860 Review. Hungarian.
The future of somatostatin analogue therapy.
Stewart PM, James RA. Stewart PM, et al. Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):409-18. doi: 10.1053/beem.1999.0031. Baillieres Best Pract Res Clin Endocrinol Metab. 1999. PMID: 10909432 Review.

See all similar articles

Cited by

Acromegaly: role of surgery in the therapeutic armamentarium.
Guinto G, Abdo M, Zepeda E, Aréchiga N, Mercado M. Guinto G, et al. Int J Endocrinol. 2012;2012:306094. doi: 10.1155/2012/306094. Epub 2012 Nov 12. Int J Endocrinol. 2012. PMID: 23209463 Free PMC article.
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V; Australasian Gastro-Intestinal Trials Group (AGITG) Ag0001H Investigators. Cebon J, et al. Br J Cancer. 2006 Oct 9;95(7):853-61. doi: 10.1038/sj.bjc.6603325. Epub 2006 Sep 5. Br J Cancer. 2006. PMID: 16953241 Free PMC article. Clinical Trial.
Somatostatin-dopamine ligands in the treatment of pituitary adenomas.
Saveanu A, Jaquet P. Saveanu A, et al. Rev Endocr Metab Disord. 2009 Jun;10(2):83-90. doi: 10.1007/s11154-008-9086-0. Epub 2008 Jul 24. Rev Endocr Metab Disord. 2009. PMID: 18651224 Review.
Efficacy of long-term lanreotide treatment in patients with acromegaly.
Toledano Y, Rot L, Greenman Y, Orlovsky S, Pauker Y, Olchovsky D, Eliash A, Bardicef O, Makhoul O, Tsvetov G, Gershinsky M, Cohen-Ouaqnine O, Ness-Abramof R, Adnan Z, Ilany J, Guttmann H, Sapir M, Benbassat C, Shimon I. Toledano Y, et al. Pituitary. 2009;12(4):285-93. doi: 10.1007/s11102-009-0172-4. Pituitary. 2009. PMID: 19266287
Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.
Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME. Kiseljak-Vassiliades K, et al. Mol Cell Endocrinol. 2015 Dec 5;417:73-83. doi: 10.1016/j.mce.2015.09.016. Epub 2015 Sep 21. Mol Cell Endocrinol. 2015. PMID: 26391562 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

K08 DK 02561/DK/NIDDK NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information